Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
The Lancet. Haematology
|
October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study
Thomas Martin, Yi Lin, Mounzer Agha, et al.
Advances in Therapy
|
May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Noemi Puig, Joris Diels, Suzy van Sanden, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J Costa, Yi Lin, R Frank Cornell, et al.
Leukemia
|
September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology
|
January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Leukemia
|
May 28, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Tineke Casneuf, Homer C Adams, Niels W C J van de Donk, et al.
Blood
|
September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Adam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Current Medical Research and Opinion
|
July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
Sharmila Raghunandan, Melinda Pauly, William G Blum, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
The Lancet. Haematology
|
October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study
Thomas Martin, Yi Lin, Mounzer Agha, et al.
Advances in Therapy
|
May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Noemi Puig, Joris Diels, Suzy van Sanden, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J Costa, Yi Lin, R Frank Cornell, et al.
Leukemia
|
September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology
|
January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Leukemia
|
May 28, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Tineke Casneuf, Homer C Adams, Niels W C J van de Donk, et al.
Blood
|
September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Adam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Current Medical Research and Opinion
|
July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Luciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
Sharmila Raghunandan, Melinda Pauly, William G Blum, et al.
Page
of 8